On Monday, March 31st, Vertex (VRTX) announced, through an abstract, the interim results of an open-label phase 2 trial for Telaprevir for treatment of Hepatitis C. 26 of 32 patients who previously failed other therapies (81%) experienced rapid virologic response [RVR] after four weeks of treatment. Even though these rates may not be sustained in longer term, chances are a good portion of these patients will be cured.
26 из 32 неответчиков достигли раннего ответа с новым разрабатываемым лекарством Telaprevir.
Так что будущее выглядит не плохо.
